IMMUNOTHERAPY IN PEDIATRIC ONCOLOGY : Into the Twenty-First Century - 08/09/11
Résumé |
Interest in immunotherapy for human malignancy has existed for decades but has borne little fruit. Over the last decade, however, significant advances have been made in our understanding of anti–tumor immunity, and these have been translated into numerous clinical studies and protocols. Immunotherapy has come of age in a few select instances and should see application in more areas in the near future.18, 87 Table 1 and Table 2 summarize recent clinical trials using monoclonal antibody and cytokine-based approaches to tumor immunotherapy.* In this article, however, the discussion is limited to manipulations of the cellular immune system. This article is divided into two sections. The generation of tumor-specific lymphocyte preparations is discussed in the first section. The authors focus on therapies that limit the graft-versus-host disease effect (GVHD) and expand the graft-versus-leukemia (GVL) effect.91 Also, two other examples of immunotherapy that have been implemented in the bone marrow transplant setting are outlined: immunotherapy of Epstein-Barr virus (EBV)–associated post-transplant lymphoma and immunotherapy as prophylaxis for cytomegalovirus (CMV) disease. We have omitted the vast literature that pertains to expanding tumor-infiltrating lymphocytes, which has been specifically developed for the treatment of melanoma.22, 80 The topic is rich enough that it deserves attention in its own right. In the second section of this article the authors focus on the production of tumor cell vaccines and on incorporating the recent advances in our understanding of dendritic cell biology into the cancer vaccine research effort.
Le texte complet de cet article est disponible en PDF.Plan
| Address reprint requests to James Casper, MD, Midwest Children's Cancer Center, Medical College of Wisconsin, Room 3040, 8701 Watertown Plank Road, Milwaukee, WI 53226 |
Vol 19 - N° 2
P. 309-326 - mai 1999 Retour au numéro
Article précédent
- SIGNAL TRANSDUCTION : Lessons Learned from Rare Pediatric Immunodeficiencies
- Shai Y. Cohen, Chaim M. Roifman
- EOSINOPHILIA IN CHILDHOOD
- Michael J. Chusid
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?